Oryzon Genomics (ORY.MC)

Executive Summary

Oryzon Genomics is a clinical-stage biopharmaceutical company based in Barcelona, Spain, pioneering targeted epigenetic therapies for oncology and central nervous system (CNS) disorders. The company's proprietary platform focuses on LSD1 inhibition, with two lead assets: iadademstat (oncology) and vafidemstat (CNS). Iadademstat is being evaluated in combination regimens for acute myeloid leukemia (AML) and extensive-stage small cell lung cancer (ES-SCLC), while vafidemstat has completed Phase 2 trials in borderline personality disorder and Alzheimer's disease. Although the Phase 2 trial of iadademstat plus paclitaxel in SCLC was terminated, a new Phase 1 trial combining iadademstat with atezolizumab in ES-SCLC began recruiting in January 2026, reflecting the company's adaptive strategy. Oryzon's pipeline also includes Phase 1 trials for iadademstat with gilteritinib and with azacitidine/venetoclax in AML. With limited cash runway and a market cap around $217 million, the company is at a critical juncture, relying on upcoming data readouts to demonstrate proof-of-concept and potentially secure partnerships. Upcoming catalysts include initial data from the iadademstat-atezolizumab Phase 1 trial in ES-SCLC, which could provide early efficacy signals in a high-need indication. Additionally, results from the iadademstat-gilteritinib Phase 1 trial in relapsed/refractory AML are expected, building on prior data. Finally, potential licensing or partnership deals for vafidemstat in CNS indications or iadademstat in oncology could provide non-dilutive funding and validation. These events could significantly impact Oryzon's valuation and trajectory, though the early-stage nature and terminated trials warrant cautious optimism.

Upcoming Catalysts (preview)

• Q3 2026Interim data from iadademstat + atezolizumab Phase 1 trial in ES-SCLC40% success
• Q2 2026Final data from iadademstat + gilteritinib Phase 1 trial in relapsed/refractory AML60% success
• H2 2026Partnership or licensing deal for vafidemstat or iadademstat30% success